Independent
Tenure on this board
1.2 yrs
Also a director at
Alnylam Pharmaceuticals Inc (ALNY)Beone Medicines Ltd (ONC)
Meeting calendar
PCVX · Annual meeting · Monday, June 15, 2026
Vaxcyte Inc
3 nominees · 3 ballot items.
Election of three Class III directors; ratification of Deloitte & Touche LLP as independent registered public accounting firm; advisory approval of named executive officer compensation.
Market cap
$8.1B
1Y TSR
+58.3%
Board grade
C
Record date
Apr 20, 2026
Filing
DEF 14A
Meeting concluded · Jun 15, 2026
Follow how the vote landed and what changed on Vaxcyte Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Class III Directors
ManagementBoard: FORElect three nominees (Olivier Brandicourt, Halley Gilbert, Grant E. Pickering) to serve as Class III directors until the 2029 Annual Meeting.
- 2
Ratification of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
More detail
This management proposal asks stockholders to ratify the Audit Committee’s selection of Deloitte & Touche LLP as the independent registered public accounting firm for 2026. Management is seeking ratification as a matter of good corporate practice, although neither the bylaws nor Delaware law require stockholder approval; ratification provides a stockholder signal of support for the engagement. Deloitte has been the auditor since 2017, providing continuity in audit oversight, and the Audit Committee retains authority to change auditors even if ratified. The proposal is routine under Nasdaq rules and typically receives favorable votes; the board recommends a vote FOR, citing the Audit Committee review of audit fees, independence and pre-approval procedures. The proxy discloses audit and tax fees for 2025 and that the Audit Committee has determined that non-audit services do not impair auditor independence. Investors should consider auditor tenure, fees, and the board’s oversight when evaluating the proposal.
- 3
Advisory Approval of Named Executive Officer Compensation (Say-on-Pay
ManagementBoard: FORNon-binding, advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the proxy statement.
More detail
This management proposal requests an advisory "say-on-pay" vote approving NEO compensation as disclosed in the proxy. Management seeks shareholder endorsement of its compensation philosophy—large proportion of at-risk pay, alignment to performance, and specific 2025 actions such as base salary increases, annual bonuses and equity grants. The board frames recent outreach and responsive changes (commitment to limit one-time awards) to address prior shareholder concerns after a 64% approval in 2025. Although non-binding, the result is used by the Compensation Committee to adjust practices. Investors should weigh the company's pay-for-performance disclosures, the Special Outperformance awards granted in 2024 and subsequent engagement and commitments, and compensation committee independence when evaluating the proposal.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
6.3 yrs
Also a director at
Cytomx Therapeutics Inc (CTMX)Arcutis Biotherapeutics Inc (ARQT)
Not independent
Tenure on this board
12.7 yrs
Also a director at
Leonabio Inc (LONA)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 11.2% | 16,166,502 | $936M |
| 2 | T. Rowe Price Investment Management, Inc. | 8.4% | 12,126,017 | $705M |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 7.9% | 11,474,599 | $667M |
| 4 | FMR LLC | 7.5% | 10,860,671 | $631M |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.3% | 6,279,545 | $365M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 6,266,701 | $364M |
| 7 | BlackRock, Inc. | 3.8% | 5,516,667 | $321M |
| 8 | WELLINGTON MANAGEMENT GROUP LLP | 3.3% | 4,829,118 | $281M |
| 9 | Paradigm Biocapital Advisors LP | 3.3% | 4,793,020 | $279M |
| 10 | STATE STREET CORP | 3.1% | 4,440,519 | $258M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Vaxcyte Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Apogee Therapeutics IncAPGE
Special meeting·Aug 11, 2026·$10.1B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.7B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$3.9B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.6B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.5B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Reference
Frequently asked questions
- When is the Vaxcyte Inc 2026 annual meeting?
- Vaxcyte Inc (PCVX) holds its 2026 annual shareholder meeting on Monday, June 15, 2026.
- What is the record date for the Vaxcyte Inc 2026 meeting?
- The record date for the Vaxcyte Inc 2026 meeting is Monday, April 20, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Vaxcyte Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Vaxcyte Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Vaxcyte Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Vaxcyte Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.